Nilotinib Leukemia Trial ICORG number 08-02 Completes Accrual

The ICORG 08-02 Nilotinib study has reached its target accrual of 60 patients in May 2011. The last 8 patients were accrued within 8 weeks, just making the mid-May deadline. As a result of this great study teamwork and effort we are able to report on the primary objective for all 60 patients. Upon study completion an abstract has been recently submitted to a top U.S. meeting (American Society of Hematology (ASH)) and we are hopeful that it will be accepted as an oral presentation at the next ASH meeting in December 2011.



American Society of Clinical Oncology (ASCO) Award

 

A medical oncology registrar, Dr. Greg Korpanty, working with Dr. Bryan Hennessy has just recently won a prestigious merit award from the American Society of Clinical Oncology (ASCO) that will be presented to him at the annual meeting of ASCO in June in Chicago. The award was given for a research project entitled ‘Loss of heterozygosity (LOH) as a measure of whole genome instability in ovarian cancer correlates with clinical outcomes’.
 
This research will also be highlighted by an expert discussant at the annual meeting in Chicago as one of the outstanding research abstracts submitted to ASCO this year.





ICORG’s new Chair Dr Paul Browne

ICORG’s new Chair Dr Paul Browne, Consultant Haematologist, St James’s Hospital, took up his four year term of office on 1st January 2009.

We would like to welcome ICORG’s new Chair, Dr Paul Browne, Consultant Haematologist, St James’s Hospital, who takes up his four year term of office on 1st January 2009.


Newest Member of ICORG’s GCO team

The ICORG Pharmacovigilance Unit has recently expanded and is pleased to welcome Armelle Donohoe, PhV Consultant and Sandra Boldrin, PhV Associate.

Armelle has over ten years experience in pharmacovigilance, and Sandra has worked in the area for two years.

Sandra is now the third ICORG employee to successfully complete the EMEA’s EudraVigilance training programme.

For more information on the ICORG group structure click here